DE602007011923D1 - Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine - Google Patents

Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine

Info

Publication number
DE602007011923D1
DE602007011923D1 DE602007011923T DE602007011923T DE602007011923D1 DE 602007011923 D1 DE602007011923 D1 DE 602007011923D1 DE 602007011923 T DE602007011923 T DE 602007011923T DE 602007011923 T DE602007011923 T DE 602007011923T DE 602007011923 D1 DE602007011923 D1 DE 602007011923D1
Authority
DE
Germany
Prior art keywords
hepatocytenwachstumsfaktor
hgf
binding proteins
proteins
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007011923T
Other languages
German (de)
English (en)
Inventor
William M Winston
Kirk S Wright
May Han
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
Arnold Horwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aveo Pharmaceuticals Inc
Xoma Technology Ltd USA
Original Assignee
Aveo Pharmaceuticals Inc
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc, Xoma Technology Ltd USA filed Critical Aveo Pharmaceuticals Inc
Publication of DE602007011923D1 publication Critical patent/DE602007011923D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DE602007011923T 2006-06-02 2007-06-01 Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine Active DE602007011923D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86050906P 2006-11-21 2006-11-21
PCT/US2007/012939 WO2007143090A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Publications (1)

Publication Number Publication Date
DE602007011923D1 true DE602007011923D1 (de) 2011-02-24

Family

ID=38802077

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007011923T Active DE602007011923D1 (de) 2006-06-02 2007-06-01 Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine

Country Status (20)

Country Link
US (5) US7649083B2 (enExample)
EP (2) EP2027156B9 (enExample)
JP (3) JP4686634B2 (enExample)
KR (1) KR101196060B1 (enExample)
AR (1) AR061171A1 (enExample)
AT (1) ATE495195T1 (enExample)
AU (1) AU2007254942B2 (enExample)
BR (1) BRPI0712222B1 (enExample)
CA (1) CA2654025C (enExample)
CY (1) CY1111714T1 (enExample)
DE (1) DE602007011923D1 (enExample)
DK (1) DK2027156T3 (enExample)
IL (2) IL195037A (enExample)
MX (1) MX2008014829A (enExample)
NO (1) NO345476B1 (enExample)
NZ (1) NZ573818A (enExample)
PL (1) PL2027156T3 (enExample)
PT (1) PT2027156E (enExample)
SG (1) SG158112A1 (enExample)
WO (1) WO2007143090A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101254371B1 (ko) 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
WO2007143098A2 (en) * 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
EP2027156B9 (en) * 2006-06-02 2011-03-30 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
US20080233660A1 (en) * 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
HRP20151261T1 (hr) 2007-07-02 2016-01-01 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za lijeäśenje i dijagnosticiranje raka
EA201000903A1 (ru) 2007-11-30 2011-02-28 Калобиос Фармасьютикалс, Инк. Антитела к pcrv-антигену pseudomonas aeruginosa
AU2009223161B2 (en) * 2008-03-14 2014-10-30 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
JP5972573B2 (ja) 2008-05-29 2016-08-17 ギャラクシー バイオテック， エルエルシー 塩基性線維芽細胞成長因子に対するモノクローナル抗体
DK2365828T3 (en) 2008-11-07 2014-12-08 Galaxy Biotech Llc Monoclonal antibodies against fibroblast second
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
BR112013004673A8 (pt) 2010-08-31 2018-01-02 Genentech Inc biomarcadores e métodos de tratamento.
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
BR112014000765A2 (pt) 2011-07-15 2017-06-13 Oncomed Pharm Inc agentes de ligação a rspo e seus usos
KR20140067052A (ko) 2011-09-09 2014-06-03 암젠 인코퍼레이티드 식도암 및 위암 환자들에서 항-간세포 성장 인자（“ｈｇｆ”） 항체들의 유효성을 예측하기 위한 ｃ―ｍｅｔ 단백질의 용도
RU2014114617A (ru) 2011-09-19 2015-10-27 Дженентек, Инк. Комбинированные виды лечения, содержащие антагонисты с-мет и антагонисты b-raf
MX2015000565A (es) 2012-07-13 2015-04-10 Oncomed Pharm Inc Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos.
MX2015010791A (es) 2013-02-22 2015-11-26 Hoffmann La Roche Metodos para tratar el cancer y prevenir la resistencia a farmacos.
US9062104B2 (en) * 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
TW201444868A (zh) * 2013-03-14 2014-12-01 Alder Biopharmaceuticals Inc Ｈｇｆ抗體及其組成物
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
WO2014166029A1 (zh) * 2013-04-07 2014-10-16 永卓博济(上海)生物医药技术有限公司 针对表皮生长因子受体的抗体
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP3146071B1 (en) 2014-05-23 2020-09-02 F. Hoffmann-La Roche AG Mit biomarkers and methods using the same
MA40363A (fr) * 2014-08-15 2017-06-21 Oncomed Pharm Inc Agents de liaison de rspo1 et leurs utilisations
JP2017528523A (ja) 2014-09-16 2017-09-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 線維性疾患の治療
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
JP2022543555A (ja) 2019-08-12 2022-10-13 インテアールエヌエー テクノロジーズ ビー．ヴイ． ｍｉＲＮＡ－１９３ａに関する新たな処置
US20230136088A1 (en) 2020-02-28 2023-05-04 Interna Technologies B.V. miRNA-193a for Promoting Immunogenic Cell Death
WO2022042673A1 (zh) * 2020-08-28 2022-03-03 江苏恒瑞医药股份有限公司 用于降低异源多肽末端异质性的信号肽
JP2024516699A (ja) 2021-05-05 2024-04-16 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｂｍａ０３１抗原結合ポリペプチド

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
JPH08500962A (ja) 1992-02-06 1996-02-06 クリエイティブ バイオモレキュルズ，インコーポレイテッド 癌マーカー用生物合成結合蛋白質
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US7459536B1 (en) * 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
MXPA05000511A (es) * 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
KR101254371B1 (ko) 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
KR100556660B1 (ko) * 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
KR20080026562A (ko) * 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2027156B9 (en) 2006-06-02 2011-03-30 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
WO2007143098A2 (en) 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
KR100881825B1 (ko) * 2007-07-27 2009-02-03 주식회사 하이닉스반도체 반도체 소자 및 그 제조 방법

Also Published As

Publication number Publication date
JP2011072318A (ja) 2011-04-14
CA2654025C (en) 2016-08-02
PT2027156E (pt) 2011-04-18
SG158112A1 (en) 2010-01-29
HK1129395A1 (en) 2009-11-27
ATE495195T1 (de) 2011-01-15
DK2027156T3 (da) 2011-04-26
BRPI0712222B1 (pt) 2021-10-13
IL195037A0 (en) 2011-08-01
EP2027156B9 (en) 2011-03-30
US8580930B2 (en) 2013-11-12
AU2007254942A1 (en) 2007-12-13
AR061171A1 (es) 2008-08-06
AU2007254942A2 (en) 2009-05-28
IL195037A (en) 2015-08-31
CY1111714T1 (el) 2015-10-07
JP4686634B2 (ja) 2011-05-25
AU2007254942B2 (en) 2011-10-27
JP5735476B2 (ja) 2015-06-17
WO2007143090A2 (en) 2007-12-13
US20100173362A1 (en) 2010-07-08
US7943344B2 (en) 2011-05-17
US8273355B2 (en) 2012-09-25
CA2654025A1 (en) 2007-12-13
US20080108565A1 (en) 2008-05-08
KR20090027226A (ko) 2009-03-16
IL219654A0 (en) 2012-06-28
NO20085421L (no) 2009-02-27
JP2009539347A (ja) 2009-11-19
WO2007143090A3 (en) 2008-03-13
EP2361934A3 (en) 2011-11-02
PL2027156T3 (pl) 2011-06-30
US9096664B2 (en) 2015-08-04
JP2013090632A (ja) 2013-05-16
NO345476B1 (no) 2021-02-22
AU2007254942A8 (en) 2009-02-05
US7649083B2 (en) 2010-01-19
MX2008014829A (es) 2009-01-29
NZ573818A (en) 2011-09-30
EP2027156A2 (en) 2009-02-25
KR101196060B1 (ko) 2012-11-01
EP2361934A2 (en) 2011-08-31
US20130203963A1 (en) 2013-08-08
BRPI0712222A2 (pt) 2012-01-10
US20110229462A1 (en) 2011-09-22
US20140178935A1 (en) 2014-06-26
EP2027156B1 (en) 2011-01-12

Similar Documents

Publication Publication Date Title
DE602007011923D1 (de) Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine
NO20201120A1 (no) Bindingsvirkninger
DK2046826T3 (da) Exendin-fusionsproteiner
DK3339445T3 (da) Interleukin -13 bindende proteiner
DK3118221T3 (da) Proteiner
DK1776383T3 (da) Bindingsmolekyler
EP2215246A4 (en) PROTEIN SCAFFOLDS
DK1999154T3 (da) Fremstillede heterodimere proteindomæner
DK2094292T3 (da) Salpeteroxid-blokeret tværbundet tetramerisk hæmoglobin
SI2126093T1 (sl) Izboljšanje priprave proteinov
BRPI0814971A2 (pt) Proteína
DK1885966T3 (da) Forbedret hoved-t-forbindelse
DK1809660T3 (da) Thymus-specifikt protein
DE502005004418D1 (de) Turbolader
EP1932681A4 (en) LEVER ARCH FILES
DK2081952T3 (da) Peptider
AT504183A3 (de) Skibindungssystem
DK2219663T3 (da) Revers-protein
FI20050547A0 (fi) Side
FI20041026A0 (fi) Sidontalaite
ITCN20060002A1 (it) Imbiellaggio martino
FI20050718A0 (fi) Sidontalaite
FI20050349A0 (fi) Sidontalaite
FI20050009A0 (fi) Sidontalaite
FI20050927A0 (fi) Sidontalaite